ERBB2 and breast cancer: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have been increasingly used in the setting of advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer, as well as in early disease [1].